C. Sisk

发表

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.

R. Califf, R. Giugliano, E. Braunwald, 2008, American heart journal.

Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.

J. Mckenney, D. Tribble, S. Liu, 2011, American heart journal.

Effects of Age, Sex, and Obesity on the Single‐Dose Pharmacokinetics of Omarigliptin in Healthy Subjects

D. Tatosian, E. Kauh, J. Wagner, 2016, Clinical pharmacology in drug development.

Incidence of hypersensitivity and anaphylaxis with sugammadex.

J. McCrea, C. Assaid, W. Herring, 2018, Journal of clinical anesthesia.

Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.

C. Ballantyne, T. Pearson, E. Veltri, 2007, The American journal of cardiology.

Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study).

G. Lip, J. Le Heuzey, H. Crijns, 2014, The American journal of cardiology.

Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis.

T. Starc, Shailendra B. Patel, G. Salen, 2006, Gastroenterology.

Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia

C. Ballantyne, R. Pasternak, J. Paolini, 2009 .

PHARMACOKINETICS Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulation

A. Zandvliet, F. Aarle, R. Greef, 2016 .

Identification of genes affecting apolipoprotein B secretion following siRNA-mediated gene knockdown in primary human hepatocytes.

B. Hubbard, M. Tudor, Liangsu Wang, 2012, Atherosclerosis.

Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial

Yue Shentu, Gregory T. Golm, Y. Shentu, 2015, Drugs & Aging.

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

M. Marre, N. Barzilai, B. Goldstein, 2013, Diabetes Care.

Ef fi cacy and Safety of Sitagliptin Versus Glipizide in PatientsWith Type 2 Diabetes andModerate-to-Severe Chronic Renal Insuf fi ciency

Gregory, Goldstein, T., 2012 .

Efficacy and safety of sitagliptin and the fixed‐dose combination of sitagliptin and metformin vs. pioglitazone in drug‐naïve patients with type 2 diabetes

B. Goldstein, S. Engel, K. Kaufman, 2011, International journal of clinical practice.

Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.

B. Goldstein, S. Engel, G. Golm, 2011, Diabetes research and clinical practice.

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.

Daniel Bloomfield, J. Mckenney, R. Pasternak, 2009, American heart journal.

A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans

C. Beals, R. Carey, M. Malice, 2012, Journal of hypertension.

Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome

S. Shahinfar, G. Gleim, R. Massaad, 2013, Pediatric Nephrology.

Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.

J. Mckenney, M. Davidson, D. Maccubbin, 2011, International journal of cardiology.

The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy

D. Watson, D. Maccubbin, J. Norquist, 2011, International journal of clinical practice.

Safety of extended-release niacin/laropiprant in patients with dyslipidemia.

J. Mckenney, C. Ballantyne, J. Paolini, 2010, Journal of clinical lipidology.

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.

R. Pasternak, J. Paolini, M. Davidson, 2009, The American journal of cardiology.

Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

R. Pasternak, J. Paolini, H. Bays, 2008, International journal of clinical practice.

Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.

C. Ballantyne, R. Pasternak, J. Paolini, 2008, Cardiology clinics.

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

A. Maclean, P. Brudi, E. Brinton, 2016, Lipids in Health and Disease.

Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose

P. Canner, D. Maccubbin, C. Sisk, 2013, International journal of clinical practice.

Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.

C. Ballantyne, G. Gleim, Nancy Liu, 2012, Journal of clinical lipidology.

Vorapaxar, an oral PAR‐1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone

T. Kosoglou, P. Statkevich, M. Hanson, 2015, Clinical pharmacology in drug development.

Losartan and enalapril are comparable in reducing proteinuria in children.

S. Shahinfar, G. Gleim, R. Massaad, 2012, Kidney international.

Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

H. Bays, Q. Dong, D. Maccubbin, 2012, American Journal of Cardiovascular Drugs.

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

A. Maclean, P. Brudi, E. Brinton, 2016, Lipids in Health and Disease.

Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: results from a randomised placebo-controlled clinical trial

J. Paolini, H. Bays, D. Watson, 2008, International journal of clinical practice.

Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus *

N. Chung, A. Johnson‐Levonas, C. Allen, 2007, Diabetes, obesity & metabolism.

Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects

J. Wagner, P. De Kam, L. Wenning, 2015, American journal of therapeutics.

Efficacy and safety of ezetimibe 40 mg vs. ezetimibe 10 mg in the treatment of patients with homozygous sitosterolaemia

D. Lütjohann, K. von Bergmann, T. Musliner, 2008, International journal of clinical practice.

The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy

D. Maccubbin, C. Sisk, A. Trovato, 2013, International journal of clinical practice.

Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

V. Elinoff, A. Elis, D. Maccubbin, 2008, International journal of clinical practice.

Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years

D. Maccubbin, J. Strony, C. Sisk, 2008, International journal of clinical practice.

Extended‐release niacin/laropiprant lipid‐altering consistency across patient subgroups

D. Maccubbin, C. Sisk, Harold E. Bays, 2011, International journal of clinical practice.

Efficacy and safety of extended‐release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia

J. Paolini, R. Češka, D. Maccubbin, 2010, International journal of clinical practice.